May 26 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH U.S. FDA FOR MULTINATIONAL PHASE 2B/3 HUMAN STUDY TO EVALUATE IFENPRODIL FOR COVID-19
* ALGERNON - CAUTIONS CO IS NOT MAKING ANY EXPRESS OR IMPLIED CLAIMS IFENPRODIL IS EFFECTIVE TREATMENT FOR COVID-19 VIRUS